Evolent Health, Inc. (NYSE:EVH) CFO John Paul Johnson Sells 44,693 Shares of Stock

Evolent Health, Inc. (NYSE:EVH) CFO John Paul Johnson sold 44,693 shares of the stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total value of $1,340,790.00. Following the sale, the chief financial officer now directly owns 171,207 shares in the company, valued at $5,136,210. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Evolent Health Price Performance

Shares of NYSE:EVH opened at $31.62 on Tuesday. The firm’s 50 day simple moving average is $22.68 and its two-hundred day simple moving average is $26.56. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.02 and a quick ratio of 1.02. The company has a market capitalization of $3.67 billion, a P/E ratio of -25.30 and a beta of 1.54. Evolent Health, Inc. has a 1-year low of $17.98 and a 1-year high of $35.00.

Evolent Health (NYSE:EVH) last released its earnings results on Thursday, August 8th. The technology company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.09. Evolent Health had a negative net margin of 5.07% and a positive return on equity of 6.90%. The company had revenue of $647.10 million for the quarter, compared to analysts’ expectations of $636.46 million. During the same quarter in the previous year, the company earned $0.06 EPS. Evolent Health’s revenue for the quarter was up 37.9% on a year-over-year basis. Research analysts expect that Evolent Health, Inc. will post 0.9 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $42.00 price objective on shares of Evolent Health in a report on Monday. Stephens restated an “overweight” rating and set a $42.00 price target on shares of Evolent Health in a research note on Tuesday, July 30th. JMP Securities lowered their price objective on shares of Evolent Health from $34.00 to $31.00 and set a “market outperform” rating on the stock in a research note on Friday, August 9th. Truist Financial raised shares of Evolent Health from a “hold” rating to a “buy” rating and raised their price objective for the stock from $28.00 to $33.00 in a report on Friday, August 9th. Finally, JPMorgan Chase & Co. upped their target price on shares of Evolent Health from $36.00 to $45.00 and gave the company an “overweight” rating in a report on Monday, August 19th. One equities research analyst has rated the stock with a sell rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $40.40.

Hedge Funds Weigh In On Evolent Health

Hedge funds have recently made changes to their positions in the business. Scout Investments Inc. bought a new stake in Evolent Health during the 1st quarter valued at approximately $5,760,000. Zevenbergen Capital Investments LLC raised its position in shares of Evolent Health by 126.5% during the first quarter. Zevenbergen Capital Investments LLC now owns 565,625 shares of the technology company’s stock valued at $18,547,000 after buying an additional 315,875 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Evolent Health by 86.7% in the first quarter. BNP Paribas Financial Markets now owns 99,126 shares of the technology company’s stock worth $3,250,000 after buying an additional 46,024 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Evolent Health by 11.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 717,334 shares of the technology company’s stock worth $23,522,000 after acquiring an additional 75,376 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Evolent Health during the fourth quarter worth $43,759,000.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.